基于Oncomine数据库分析分泌性磷蛋白1在肝细胞癌中的表达及临床意义

目的 分析分泌性磷蛋白1(SPP1)在肝细胞癌中的表达,探索其对肝癌患者预后的影响.方法 基于Oncomine数据库,对肝细胞癌中的SPP1差异表达情况进行分析,探讨其意义;利用Kaplan Meier-Plotter在线分析工具,对患者生存情况进行分析;基于String数据库在线构建蛋白互作网络.结果 在筛选到的4项...     

Sofosbuvir plus ribavirin with or without peginterferon for the treatment of hepatitis C virus: Results from a phase 3b study in China

Background and Aim

Sofosbuvir is a nucleotide analog inhibitor of the hepatitis C virus (HCV) NS5B RNA polymerase with pangenotypic potency. This phase 3b study evaluated the safety and efficacy of sofosbuvir + ribavirin ± peginterferon in Chinese patients infected with HCV genotype 1, 2, 3, or 6.

Methods

Patients with genotype 1 or 6 received sofosbuvir + peginterferon/ribavirin for 12 weeks or sofosbuvir + ribavirin for 24 weeks, depending on prior treatment and interferon eligibility. Patients with genotype 2 or 3 received sofosbuvir + ribavirin for 12 or 24 weeks, respectively. The primary endpoint was sustained virologic response at 12 weeks after the end of treatment (SVR12).

Results

Of 389 patients, 42% had genotype 1, 16% genotype 2, 32% genotype 3, and 9% genotype 6. Half were male, 58% were treatment‐naïve, and 15% had cirrhosis. SVR12 rates for patients receiving 12 weeks of sofosbuvir + peginterferon/ribavirin were 94% (95% confidence interval [CI], 87–98%) for HCV genotype 1 and 97% (95% CI, 84–100%) for genotype 6. SVR12 rates for those receiving sofosbuvir + ribavirin for 24 weeks were 95% (95% CI, 87–99%) for genotype 1, 100% (95% CI, 40–100%) for genotype 6, and 95% (95% CI, 90–98%) for genotype 3. For genotype 2 patients receiving sofosbuvir + ribavirin for 12 weeks, the SVR12 rate was 92% (95% CI, 83–97%). Twenty patients (5%) relapsed. Ten (3%) experienced serious adverse events. Three (< 1%) discontinued treatment because of adverse events, of whom one died because of treatment‐unrelated adverse events.

Conclusions

Sofosbuvir‐based regimens were highly effective and safe in Chinese patients with HCV genotype 1, 2, 3, or 6, suggesting sofosbuvir could serve as the backbone for HCV treatment in China irrespective of genotype.     

外科治疗高分级动脉瘤性蛛网膜下腔出血的随访分析

目的探讨高分级颅内动脉瘤的治疗方式和影响预后的因素。方法回顾性分析南方医科大学第三附属医院神经外科2011年4月至2017年7月收治的24例高级别颅内动脉瘤患者的临床资料和影像资料,采用mRS量表评价患者的预后,通过单因素t检验和卡方检验分析影响预后的因素。结果预后良好12例,预后差12例。单因素分析显示患者年龄≥65岁(P=0.028)、高血压病史(P=0.041)、动脉瘤直径5mm(P=0.041)、急性脑积水(P=0.028)与预后不良有关。Hunt-HessⅣ级患者不同手术时机分组间死亡率差异有统计学意义(P=0.018);Hunt-HessⅤ级患者不同手术时机分组间死亡率差异无统计学意义(P=0.505)。结论通过积极的治疗,高级别动脉瘤性蛛网膜下腔出血患者可以取得较好的预后。患者的年龄、高血压病史、急性脑积水、动脉瘤大小与预后相关。超早期手术有助于降低Hunt-HessⅣ级患者死亡率。     

Effect of Gua Sha therapy on patients with diabetic peripheral neuropathy: A randomized controlled trial

ObjectiveTo examine the effect of Gua Sha therapy in the treatment of diabetic peripheral neuropathy (DNP).DesignAn open-label randomized controlled study was conducted with usual care as the control (60 subjects in Gua Sha group and 59 subjects in usual care group). Outcome measures included Toronto Clinical Scoring System (TCSS), Vibration Perception Threshold (VPT), Ankle Brachial Index (ABI), and fasting plasma glucose (FPG). There were 12 consecutive sessions of Gua Sha, one session per week.ResultsAfter the first cycle of Gua Sha intervention, only performance of sensory function measured by the VPT, and peripheral artery disease symptoms by the ABI were statistically significant differences between the two groups (both P values < 0.01), and the total TCSS score and the FPG level were no group differences (P = 0.14, and 0.25, respectively). At the eight-week and 12-week post intervention assessment, Gua Sha therapy significantly reduced severity of neuropathy symptoms, improved performance of sensory function, reduced peripheral artery disease, and better controlled plasma glucose by comparing with the control group (all P values < 0.01). The changes of mean scores of TCSS, VPT, ABI and the plasma glucose levels in the Gua Sha group showed a significant change from baseline to week 12, indicating that Gua Sha therapy induced progressive improvement in the management of DPN symptoms, sensory function, peripheral artery disease and glucose levels. No serious adverse events were reported in either arm. Gua Sha therapy in this study was effective, safe and well tolerated by patients.ConclusionGua Sha therapy appears to be effective at reducing the severity of DPN in a clinically relevant dimension, and at improving other health outcomes in patients with DPN. While this study found that Gua Sha therapy is a promising treatment in reducing the symptoms of patients with DPN, further, larger sample studies are required to confirm the effects of Gua Sha therapy in patients with DPN.     

家兔面神经颅外段的显微解剖

目的　探讨家兔面神经颅外段的主干及分支特点。 方法　健康家兔15只,在显微镜下解剖家兔面神经,并对其形态特点进行观测。 结果　家兔面神经出茎乳孔后分出耳后支、二腹肌支、茎突舌骨肌支及面神经主干。兔面神经主干在面部的分支有颞支、颧支、颊支、下颌缘支和颈支,其中颧支与颊支关系密切,走行过程中合成一干,然后在口角后缘分离。 结论　家兔面神经颧支与颊支在耳廓下缘前部位到口角后缘之间,分支少,神经干较粗,便于进行面神经缺损修复动物模型的建立。     

X线辐射剂量对结直肠癌细胞中microRNA-221和p57kip2表达的影响

目的 探讨不同剂量X线辐射对人结直肠癌Caco2细胞系中microRNA-221（miR-221）和p57^kip2表达的影响。方法 常规培养Caco2细胞系并分为5组,分别给予不同剂量X线（0、2、4、6和8 Gy）照射,24 h后提取细胞总RNA和蛋白质,应用real-time Q-PCR检测细胞中miR-221和p57^kip2 mRNA的表达水平,Western blot检测p57kip2蛋白的表达变化。结果 Caco2细胞系在不同照射剂量下,miR-221表达水平随着照射剂量的增加而增加,而p57kip2蛋白表达水平则随着照射剂量的增加而逐步降低,且呈剂量依赖效应,两者差异均具有统计学意义（P<0.05）。结论 放射线辐射剂量可影响结直肠癌细胞中miR-221/ p57^kip2调控通路,抑制miR-221表达可能会提高结直肠癌细胞的放射敏感度。     

Dexmedetomidine mitigates isoflurane-induced neurodegeneration in fetal rats during the second trimester of pregnancy

Dexmedetomidine has significant neuroprotective effects. However, whether its protective effects can reduce neurotoxicity caused by isoflurane in fetal brain during the second trimester of pregnancy remains unclear. In this study, timed-pregnancy rats at gestational day 14 spontaneously inhaled 1.5% isoflurane for 4 hours, and were intraperitoneally injected with dexmedetomidine at dosages of 5, 10, 20, and 20 μg/kg 15 minutes before inhalation and after inhalation for 2 hours. Our results demonstrate that 4 hours after inhaling isoflurane, 20 μg/kg dexmedetomidine visibly mitigated isoflurane-induced neuronal apoptosis, reversed downregulation of brain-derived neurotrophic factor expression, and lessened decreased spatial learning and memory ability in adulthood in the fetal rats. Altogether, these findings indicate that dexmedetomidine can reduce neurodegeneration induced by isoflurane in fetal rats during the second trimester of pregnancy. Further, brain-derived neurotrophic factor participates in this process.